Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28826192 | 0.88 | SSTR4 (0.47) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL24928078 | 0.86 | CTSK (0.41) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL31368050 | 0.86 | CTSK (0.41) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL24928082 | 0.86 | CTSK (0.41) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL2183768 | 0.84 | CTSK (0.44) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL21335582 | 0.84 | CTSK (0.44) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL24850160 | 0.84 | CTSK (0.46) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL22590344 | 0.84 | CTSK (0.46) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL18909589 | 0.84 | CTSK (0.46) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL23162417 | 0.83 | CTSK (0.43) | CTSKCA1CA2BTKCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | CTSK 1559/4885CA1 3988/4885CA2 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.